338 related articles for article (PubMed ID: 18553995)
1. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
2. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
3. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
4. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
6. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry.
Matta A; DeSouza LV; Shukla NK; Gupta SD; Ralhan R; Siu KW
J Proteome Res; 2008 May; 7(5):2078-87. PubMed ID: 18407684
[TBL] [Abstract][Full Text] [Related]
8. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
Matharoo-Ball B; Ball G; Rees R
Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
[TBL] [Abstract][Full Text] [Related]
9. Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer.
DeSouza LV; Romaschin AD; Colgan TJ; Siu KW
Anal Chem; 2009 May; 81(9):3462-70. PubMed ID: 19323455
[TBL] [Abstract][Full Text] [Related]
10. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
11. A novel multidimensional protein identification technology approach combining protein size exclusion prefractionation, peptide zwitterion-ion hydrophilic interaction chromatography, and nano-ultraperformance RP chromatography/nESI-MS2 for the in-depth analysis of the serum proteome and phosphoproteome: application to clinical sera derived from humans with benign prostate hyperplasia.
Garbis SD; Roumeliotis TI; Tyritzis SI; Zorpas KM; Pavlakis K; Constantinides CA
Anal Chem; 2011 Feb; 83(3):708-18. PubMed ID: 21174401
[TBL] [Abstract][Full Text] [Related]
12. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia.
Xu K; Ling MT; Wang X; Wong YC
Prostate Cancer Prostatic Dis; 2006; 9(3):293-7. PubMed ID: 16683014
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
14. Preliminary studies on the isolation and characterization of predominant prostatic proteins.
Lombardo ME; Meyer-Siegler K; Hakky SI; Hudson PB
Prostate; 1996 Dec; 29(6):381-5. PubMed ID: 8977635
[TBL] [Abstract][Full Text] [Related]
15. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
16. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
Cheng HL; Huang HJ; Ou BY; Chow NH; Chen YW; Tzai TS; Wu CJ; Chen SH
Proteomics Clin Appl; 2011 Apr; 5(3-4):121-32. PubMed ID: 21322116
[TBL] [Abstract][Full Text] [Related]
17. [Differentially expressed genes in prostate cancer and benign prostatic hyperplasia].
Zhang T; Xu Y; Tang H; Liu M; Ren D; Niu Y
Zhonghua Nan Ke Xue; 2004 Dec; 10(12):897-9. PubMed ID: 15638016
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer.
Roblick UJ; Bader FG; Hammarstedt L; Habermann JK; Hellman U; Becker S; Sundmacker A; Gemoll T; Zimmermann K; Auer G; Munck-Wikland E
Acta Oncol; 2008; 47(8):1493-501. PubMed ID: 18759147
[TBL] [Abstract][Full Text] [Related]
19. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens.
Huang D; Casale GP; Tian J; Wehbi NK; Abrahams NA; Kaleem Z; Smith LM; Johansson SL; Elkahwaji JE; Hemstreet GP
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1371-81. PubMed ID: 17623804
[TBL] [Abstract][Full Text] [Related]
20. Proteomics for the identification of new prostate cancer biomarkers.
Ornstein DK; Tyson DR
Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
